| abstract |
IL2 AGONISTS. The invention relates to interleukin-2 (IL2) variants. In one embodiment, IL2 variants activate effector T cells over regulatory T cells. In particular, the invention relates to a polypeptide comprising a human IL2 mutein or a functional variant of human IL2, wherein the human IL2 or its functional variant is substituted in at least one position having an acidic or basic amino acid residue in the wild-type human IL2 that contacts the alpha subunit of the aß IL2 receptor complex (IL2Raß). The invention also relates to polynucleotides encoding the polypeptides of the invention, host cells comprising the polynucleotides, pharmaceutical compositions comprising the polypeptides, polynucleotides or host cells, therapeutic or prophylactic methods of treatment using the polypeptides, polynucleotides, host cells or pharmaceutical compositions and medical preparations comprising polypeptides, polynucleotides, host cells or pharmaceutical compositions. |